Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 ...

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 vaccinations, a new study ...

Shares of Alumis (NASDAQ:ALMS) traded ~14% higher in the premarket on Tuesday after the California-based biopharma announced ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...